Investors & Media

Transformative science, targeted medicines

Blueprint Medicines, a Sanofi company, is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

SEC Filings

Search
Filing date Form Description View
4 Statement of changes in beneficial ownership of securities View HTML
0001104659-25-069388.pdf
0001104659-25-069388.rtf
0001104659-25-069388.xls
4 Statement of changes in beneficial ownership of securities View HTML
0001104659-25-069387.pdf
0001104659-25-069387.rtf
0001104659-25-069387.xls
4 Statement of changes in beneficial ownership of securities View HTML
0001104659-25-069396.pdf
0001104659-25-069396.rtf
0001104659-25-069396.xls
4 Statement of changes in beneficial ownership of securities View HTML
0001104659-25-069395.pdf
0001104659-25-069395.rtf
0001104659-25-069395.xls
SC TO-T/A Amendment to a previously filed SC TO-T View HTML
0001193125-25-160629.pdf
0001193125-25-160629.rtf
0001193125-25-160629.xls
SC 14D9/A Amendment to a previously filed SC 14D9 View HTML
0001193125-25-160643.pdf
0001193125-25-160643.rtf
0001193125-25-160643.xls
8-K Report of unscheduled material events or corporate event View HTML
0001193125-25-160804.pdf
0001193125-25-160804.rtf
0001193125-25-160804.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
25-NSE 25-NSE View HTML
0001354457-25-000693.pdf
0001354457-25-000693.rtf
0001354457-25-000693.xls
POS AM Post-effective amendment to an S-Type filing View HTML
0001193125-25-161191.pdf
0001193125-25-161191.rtf
S-8 POS Post-effective amendment to an S-8 filing View HTML
0001193125-25-161195.pdf
0001193125-25-161195.rtf